Comparing new vs. old criteria for diagnosing multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial compares two sets of diagnostic criteria (McDonald criteria 2024 vs. 2017) for multiple sclerosis in real-life settings. It aims to see which criteria work better in diagnosing MS in patients with symptoms or MRI findings that suggest the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be covered by French national health insurance.
- You must be seen at Nancy University Hospital or Metz-Thionville Regional Hospital (Mercy site) for the first time with symptoms or MRI findings that might be multiple sclerosis.
- Your doctor must think your symptoms or MRI findings could be multiple sclerosis.
- You cannot have symptoms or MRI findings that suggest another condition like neuromyelitis optica, anti-MOG disorders, sarcoidosis, or other causes such as infections or tumors.
- You must be able to have at least one brain MRI (no medical reason that prevents it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether people with relapsing-remitting MS can experience symptom flare-ups (relapses) that don't show up on MRI scans. Researchers want to understand if this happens and what it means for your care.
This study compares three types of brain MRI scans (3D FLAIR, DIR, and PSIR) to see which is best at detecting optic neuritis (inflammation of the optic nerve). It looks at scans from patients with multiple sclerosis or NMO spectrum disorder to improve diagnosis.
This trial tests a screening method to find cognitive issues early in people with multiple sclerosis. It aims to help you understand how your thinking might be affected and guide your care.
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
This study looks at why some people with relapsing-remitting multiple sclerosis (RRMS) get worse even when they don't have relapses. It uses eye scans and other tests to find early signs of progression, which could help tailor treatments.
This study compares how well two medicines, Kesimpta and Ocrevus, work for people with multiple sclerosis when used in real life. It looks at patient records to see which treatment might be more effective.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.